Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases fleshed out a proposed national HIV plan at the opening session of the Conference on Retroviruses and Opportunistic Infections this week in Seattle.

As health officials continue to urge more people at risk of becoming HIV-positive to take PrEP, the once-a-day pill that widely protects against being infected with the virus if taken as prescribed, San Francisco leaders are embracing a new dosing regimen

The number of people taking PrEP rose by nearly 30 percent from 2016 to 2017, but disparities remain, according to updated figures released this week by AIDSVu.

San Francisco will receive a grant from the Centers for Disease Control and Prevention to help close gaps and mitigate barriers in HIV prevention and care services, particularly among homeless people.

PrEP is highly effective as an HIV prevention tool, but barriers to wider access are limiting its full potential, according to recent studies.

A San Francisco man is the sixth known case of PrEP failure despite consistent use of Truvada, researchers from the Department of Public Health and UCSF reported at the IDWeek conference held in San Francisco earlier this month.

Only 4 percent of sexually active gay and bisexual men in the United States are using PrEP, according to a recently published study, showing that more must be done to reach everyone who could benefit from it.

The U.S. Food and Drug Administration has approved two new HIV treatment medications containing doravirine, a next-generation non-nucleoside reverse transcriptase inhibitor.

The latest San Francisco HIV epidemiology report shows that while the number of new infections continues to decline, African-Americans and homeless people have persistently higher infection rates and poorer outcomes.

The proportion of people with HIV who achieve viral suppression has risen dramatically across the United States over the past two decades, but young black men are not seeing the same gains, according to a new study.

Government policies can work against achieving an end to HIV by limiting access to prevention and treatment for the most heavily affected groups, according to research presented at the 22nd International AIDS Conference last week in Amsterdam.

Activists kicked off this week's 22nd International AIDS Conference in Amsterdam with calls to move the next confab out of the San Francisco Bay Area.

A new Spanish-language PrEP campaign has launched to raise awareness about the HIV prevention pill in Latino communities.

The U.S. Food and Drug Administration this week approved Truvada PrEP for adolescents, making the once-daily HIV prevention pill more widely available to a group with a disproportionately high risk of infection.